Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complete remission study
2024-519628-25-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of dupilumab and mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Primary. Planned start Apr 2025; status: authorised.
02
Drugs
dupilumabmepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-519628-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519628-25-00.